We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+33.1%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$758M
AUM Growth
+$195M
Cap. Flow
+$52.3M
Cap. Flow %
6.9%
Top 10 Hldgs %
45.66%
Holding
77
New
20
Increased
20
Reduced
12
Closed
17

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$21.6M
2
WINT
Windtree Therapeutics Inc
WINT
+$13.2M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$12.8M
4
ZGNX
Zogenix, Inc.
ZGNX
+$10.9M
5
DVAX
Dynavax Technologies
DVAX
+$10.6M

Top Sells

Rank Stock Value
1
NTUS
Natus Medical Inc
NTUS
+$29.1M
2
ALKS icon
Alkermes
ALKS
+$15.1M
3
IART icon
Integra LifeSciences
IART
+$8.91M
4
SPNC
Spectranetics Corp
SPNC
+$8.33M
5
NUVA
NuVasive, Inc.
NUVA
+$7.35M

Sector Composition

Rank Sector Weight
1 Healthcare 76.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ANTH
51
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$2.35M 0.31%
95,791
+6,729
+8% +$173K
CASM
52
DELISTED
CAS Medical Systems, Inc.
CASM
$2.29M 0.3%
1,349,796
+48,900
+4% +$76.3K
ALBO
53
DELISTED
Albireo Pharma Inc
ALBO
$2.28M 0.3%
33,333
– –
TLPH icon
54
Talphera
TLPH
$68.5M
$2.26M 0.3%
+10,000
New +$1.74M
CUTR
55
DELISTED
Cutera, Inc.
CUTR
$2.2M 0.29%
215,962
– –
EPZM
56
DELISTED
Epizyme, Inc
EPZM
$2.08M 0.27%
+100,000
New +$2.9M
GYRE icon
57
Gyre Therapeutics
GYRE
$675M
$1.24M 0.16%
+380
New +$1.5M
STRR
58
DELISTED
Star Equity Holdings
STRR
$831K 0.11%
4,490
+840
+23% +$149K
TRNX
59
DELISTED
TORNIER N V SHARES (NLD)
TRNX
$282K 0.04%
+15,000
New +$283K
STJ
60
DELISTED
St Jude Medical
STJ
$6K ﹤0.01%
+100
New +$5.79K
ALKS icon
61
Alkermes
ALKS
$8.79B
– –
-450,000
Closed -$15.1M
DGX icon
62
Quest Diagnostics
DGX
$23.3B
– –
-25,000
Closed -$1.54M
GMED icon
63
Globus Medical
GMED
$10.5B
– –
-248,767
Closed -$4.34M
IART icon
64
Integra LifeSciences
IART
$1.5B
– –
-541,627
Closed -$8.91M
INSM icon
65
Insmed
INSM
$23.5B
– –
-165,145
Closed -$2.58M
MASI
66
DELISTED
Masimo
MASI
– –
-165,837
Closed -$4.42M
NVAX icon
67
Novavax
NVAX
$1.35B
– –
-40,000
Closed -$2.52M
OFIX icon
68
Orthofix Medical
OFIX
$468M
– –
-151,523
Closed -$3.15M
NUVA
69
DELISTED
NuVasive, Inc.
NUVA
– –
-300,000
Closed -$7.35M
GWPH
70
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
– –
-332,936
Closed -$5.7M
IPCI
71
DELISTED
Intellipharmaceuticals International Inc.
IPCI
– –
-175,626
Closed -$3.44M
SPNC
72
DELISTED
Spectranetics Corp
SPNC
– –
-495,833
Closed -$8.33M
SQNM
73
DELISTED
SEQUENOM INC NEW
SQNM
– –
-600,000
Closed -$1.6M
HTWR
74
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
– –
-25,000
Closed -$1.83M
HNT
75
DELISTED
HEALTH NET INC
HNT
– –
-2,000
Closed -$63K
1 2
3
4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q4 2013 Portfolio in Review

As of Q4 2013, Broadfin Capital held 77 positions worth $758M, up 35% from $563M the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Broadfin Capital deployed $52.3M of net new capital in Q4 2013, opening 20 new positions and adding to 20 existing holdings. Its largest new stake was Sarepta Therapeutics: 726,655 shares worth $14.8M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 78% a quarter earlier.

On the sell side, the largest reduction was Natus Medical Inc, an estimated $29.1M trimmed.

  • Broadfin Capital's largest Q4 2013 buy was Sarepta Therapeutics: 726,655 shares worth $14.8M.
  • Broadfin Capital added most to Windtree Therapeutics Inc in Q4 2013, an estimated $13.2M increase.
  • Broadfin Capital's biggest Q4 2013 reduction was Natus Medical Inc, cutting an estimated $29.1M.
  • Broadfin Capital fully exited Alkermes in Q4 2013, selling an estimated $15.1M.
  • Broadfin Capital's ten largest holdings make up 46% of its $758M portfolio in Q4 2013.
  • Broadfin Capital opened 20 new positions and closed 17 in Q4 2013.
  • Broadfin Capital's portfolio value rose 35% quarter-over-quarter to $758M.

Based on Broadfin Capital's 13F filing for Q4 2013, filed 14 Feb 2014.